Ibogaine for treatment of opioid addictionUniversal Ibogaine owns the global licensing rights to the life saving protocol and is working on a clinical trial in Canada to medicalize the ibogaine molecule. It is a plant medicine that can cure someone of opioid addiction in one dose. This company is developing a worldwide treatment center network.
Pennystocks
Universal Ibogaine Stock SummaryUniversal Ibogaine Inc. is an expanding Canadian-holding company with an average volume of $139K+ in the last 3 months. The average volume of the company in the last 10 days is $81.88K with $190.74M share outstanding. The stock price when the market opened was $0.045.
UI CEO’s rapturous to work with Blue Digital Media"We are happy to have access to Blue Digital's distribution channels, as their range across borders will broaden awareness of our business to new audiences," said Nick Karos, UI's Chief Executive Officer. Because addiction knows no bounds, the remedy we seek must be global in scope." As Blue Digital Media professional radar.
$IBO CO-Founder with wide ranging work-experienceDr. Sola, a co-founder of Universal Ibogaine and a member of its Board of Directors, has effectively administered over 3,700 ibogaine treatments, more than any other doctor in the world, at an independent clinic in Cancun, Mexico, where he is a partner.
CEO highlights on the sheer extent of the research to reality ev"The significance of this occasion cannot be emphasized," said CEO Nick Karos. This is the first gathering of academic researchers, real-world technicians, and government policymakers of its sort. This event will raise awareness of ibogaine's great potential at the highest levels."
Universal Ibogaine Inc. CEO’s ecstatic to work with Blue Digital
"We are happy to have access to Blue Digital's distribution channels, as their range across borders will broaden awareness of our business to new audiences," said Nick Karos, UI's Chief Executive Officer. Because addiction knows no bounds, the remedy we seek must be global in scope." As Blue Digital Media professional radar.
$HEM announcement related to the Stock Options GrantHemostemix Inc. announced that in accordance with its stock option plan, it has granted on February 28, 2022, subject to regulatory approval, a total of 1,494,269 stock options to purchase common shares of Hemostemix to directors, officers, employees and consultants of Hemostemix